All In MedTech

FDA Clearance Tracker · P210005-S007

IC-8 Apthera Intraocular Lens (IOL)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 25, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Apr 25, 2025

Approved

Time to decision

140 days

Received Dec 6, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P210005-S007
Device name
IC-8 Apthera Intraocular Lens (IOL)
Applicant location
Irvine, CA
Received
Dec 6, 2024
Decided
Apr 25, 2025
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P210005

Device type

Device class
Class III
Regulation
21 CFR 886.3600
Specialty
Ophthalmology

Every decision under product code POE

FDA's approval statement

As written in FDA's record.

approval for updating the Instructions for Use of the IC-8 Apthera Intraocular Lens (IOL) to include the outcomes of the Continuation Post-Approval Study (PAS) SAIL-101-PAS

Source documents

Other decisions for Acu Focus, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.